Value of positron emission tomography in the diagnosis of recurrent oesophageal carcinoma

British Journal of Surgery

Volumn 91, Issue 8, 2004, Pages 1004-1009

  Kato, H ^a   Miyazaki, T ^a   Nakajima, M ^a   Fukuchi, M ^a   Manda, R ^a   Kuwano, H ^a  

^a GUNMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; ESOPHAGUS CANCER; FEMALE; FOLLOW UP; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECURRENT CANCER; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SQUAMOUS CELL CARCINOMA; COMPARATIVE STUDY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; ESOPHAGUS RESECTION; ESOPHAGUS TUMOR; METASTASIS; METHODOLOGY; MIDDLE AGED; SCINTISCANNING; TUMOR RECURRENCE;

ADULT; AGED; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 4043084865     PISSN: 00071323     EISSN: None     Source Type: Journal    
DOI: 10.1002/bjs.4595     Document Type: Article

References (39)

1. Bar-Shalom R, Valdivia AY, Blaufox MD. PET imaging in oncology. Semin Nucl Med 2000; 30: 150-185.
2. Bares R, Klever P, Hauptmann S, Hellwig D, Fass J, Cremerius U et al. F-18 fluorodeoxyglucose PET in vivo evaluation of pancreatic glucose metabolism for detection of pancreatic cancer. Radiology 1994; 192: 79-86.
3. Inoue T, Kim EE, Komaki R, Wong FC, Bassa P, Wong WH et al. Detecting recurrent or residual lung cancer with FDG-PET. J Nucl Med 1995; 36: 788-793.
4. Ahuja V, Coleman RE, Herndon J, Patz EF Jr. The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma. Cancer 1998; 83: 918-924.
5. Coleman RE. PET in lung cancer. J Nucl Med 1999; 40: 814-820.
6. Higashi K, Ueda Y, Ayabe K, Sakurai A, Seki H, Nambu Y et al. FDG-PET in the evaluation of the aggressiveness of pulmonary adenocarcinoma: correlation with histopathological features. Nucl Med Commun 2000; 21: 707-714.
7. Flanagan FL, Dehdashti F, Siegel BA, Trask DD, Sundaresan SR, Patterson GA et al. Staging of esophageal cancer with 18F-fluorodeoxyglucose positron emission tomography. AJR Am J Roentgenol 1997; 168: 417-424.
8. Block MI, Patterson GA, Sundaresan RS, Bailey MS, Flanagan FL, Dehdashti F et al. Improvement in staging of esophageal cancer with the addition of positron emission tomography. Ann Thorac Surg 1997; 64: 770-776.
9. Kole AC, Plukker JT, Nieweg OE, Vaalburg W. Positron emission tomography for staging of oesophageal and gastroesophageal malignancy. Br J Cancer 1998; 78: 521-527.
10. McAteer D, Wallis F, Couper G, Norton M, Welch A, Bruce D et al. Evaluation of 18F-FDG positron emission tomography in gastric and oesophageal carcinoma. Br J Radiol 1999; 72: 525-529.
11. Luketich JD, Friedman DM, Weigel TL, Meehan MA, Keenan RJ, Townsend DW et al. Evaluation of distant metastases in esophageal cancer: 100 consecutive positron emission tomography scans. Ann Thorac Surg 1999; 68: 1133-1136.
12. Lerut T, Flamen P, Ectors N, Van Cutsem E, Peeters M, Hiele M et al. Histopathologic validation of lymph node staging with FDG-PET scan in cancer of the esophagus and gastroesophageal junction: a prospective study based on primary surgery with extensive lymphadenectomy. Ann Surg 2000; 232: 743-752.
13. Kim K, Park SJ, Kim BT, Lee KS, Shim YM. Evaluation of lymph node metastases in squamous cell carcinoma of the esophagus with positron emission tomography. Ann Thorac Surg 2001; 71: 290-294.
14. Skehan SJ, Brown AL, Thompson M, Young JE, Coates G, Nahmias C. Imaging features of primary and recurrent esophageal cancer at FDG-PET. Radiographics 2000; 20: 713-723.
15. Flamen P, Lerut A, Van Cutsem E, Cambier JP, Maes A, De Wever W et al. The utility of positron emission tomography for the diagnosis and staging of recurrent esophageal cancer. J Thorac Cardiovasc Surg 2000; 120: 1085-1092.
16. Brucher BL, Weber W, Bauer M, Fink U, Avril N, Stein HJ et al. Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography. Ann Surg 2001; 233: 300-309.
17. Weber WA, Ott K, Becker K, Dittler HJ, Helmberger H, Avril NE et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 2001; 19: 3058-3065.
18. Flamen P, Van Cutsem E, Lerut A, Cambier JP, Haustermans K, Bormans G et al. Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer. Ann Oncol 2002; 13: 361-368.
19. Kato H, Kuwano H, Nakajima M, Miyazaki T, Yoshikawa M, Ojima H et al. Comparison between positron emission tomography and computed tomography in the use of the assessment of esophageal carcinoma. Cancer 2002; 94: 921-928.
20. Kato H, Kuwano H, Nakajima M, Miyazaki T, Yoshikawa M, Masuda N et al. Usefulness of positron emission tomography for assessing the response of neoadjuvant chemoradiotherapy in patients with esophageal cancer. Am J Surg 2002; 184: 279-283.
21. Sugimachi K, Ohno S, Matsuda H, Mori M, Matsuoka H, Kuwano H. Clinicopathologic study of early stage oesophageal carcinoma. Surgery 1989; 105: 706-710.
22. Kato H. Diagnosis and treatment of oesophageal neoplasms. Jpn J Cancer Res 1995; 86: 993-1009.
23. Glickman JN, Torres C, Wang HH, Turner JR, Shahsafaei A, Richards WG et al. The prognostic significance of lymph node micrometastasis in patients with esophageal carcinoma. Cancer 1999; 85: 769-778.
24. Ando N, Iizuka T, Kakegawa T, Isono K, Watanabe H, Ide H et al. A randomized trial of surgery with and without chemotherapy for localized squamous carcinoma of the thoracic esophagus: the Japan Clinical Oncology Group Study. J Thorac Cardiovasc Surg 1997; 114: 205-209.
25. Baba M, Aikou T, Yoshinaka H, Natsugoe S, Fukumoto T, Shimazu H et al. Long-term results of subtotal esophagectomy with three-field lymphadenectomy for carcinoma of the thoracic esophagus. Ann Surg 1994; 219: 310-316.
26. van Lanschot JJ, Tilanus HW, Voormolen MH, van Deelen RA. Recurrence pattern of oesophageal carcinoma after limited resection does not support wide local excision with extensive lymph node dissection. Br J Surg 1994; 81: 1320-1323.
27. Kato H, Tachimori Y, Watanabe H, Igaki H, Nakanishi Y, Ochiai A. Recurrent esophageal carcinoma after esophagectomy with three-field lymph node dissection. J Surg Oncol 1996; 61: 267-272.
28. Matsubara T, Ueda M, Takahashi T, Nakajima T, Nishi M. Localization of recurrent disease after extended lymph node dissection for carcinoma of the thoracic esophagus. J Am Coll Surg 1996; 182: 340-346.
29. Bhansali MS, Fujita H, Kakegawa T, Yamana H, Ono T, Hikita S et al. Pattern of recurrence after extended radical esophagectomy with three-field lymph node dissection for squamous cell carcinoma in the thoracic esophagus. World J Surg 1997; 21: 275-281.
30. Law SY, Fok M, Wong J. Pattern of recurrence after oesophageal resection for cancer: clinical implications. Br J Surg 1996; 83: 107-111.
31. Raoul JL, Le Prise E, Meunier B, Julienne V, Etienne PL, Gosselin M et al. Combined radiochemotherapy for postoperative recurrence of oesophageal cancer. Gut 1995; 37: 174-176.
32. Beck JR. Likelihood ratios. Another enhancement of sensitivity and specificity. Arch Pathol Lab Med 1986; 110: 685-686.
33. Inoue T, Oriuchi N, Kunio M, Tomiyoshi K, Tomaru Y, Aoyagi K et al. Accuracy of standardized uptake value measured by simultaneous emission and transmission scanning in PET oncology. Nucl Med Commun 1999; 20: 849-857.
34. Pham KH, Ramaswamy MR, Hawkins RA. Advances in positron emission tomography imaging for the GI tract. Gastrointest Endosc 2002; 55(Suppl): S53-S63.
35. Cremerius U, Fabry U, Neuerburg J, Zimny M, Osieka R, Buell U. Positron emission tomography with 18F-FDG to detect residual disease after therapy for malignant lymphoma. Nucl Med Commun 1998; 19: 1055-1063.
36. Gould MK, Maclean CC, Kuschner WG, Rydzak CE, Owens DK. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. JAMA 2001; 285: 914-924.
37. Bockisch A, Brandt-Mainz K, Gorges R, Muller S, Stattaus J, Antoch G. Diagnosis in medullary thyroid cancer with [18F]FDG-PET and improvement using a combined PET/CT scanner. Acta Med Austriaca 2003; 30: 22-25.
38. Kinkel K, Lu Y, Both M, Warren RS, Thoeni RF. Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): a meta-analysis. Radiology 2002; 224: 748-756.
39. Koyama K, Okamura T, Kawabe J, Ozawa N, Higashiyama S, Ochi H et al. The usefulness of 18F-FDG PET images obtained 2 hours after intravenous injection in liver tumor. Ann Nucl Med 2002; 16: 169-176.